Nonetheless, in combination with previous work in a KRAS-driven mouse model of Gorham-Stout disease, our data suggest that use of a MEK inhibitor for the treatment of lymphatic anomalies due to pathogenic variants in the RAS/MAPK pathway should be systematically evaluated in future trials (12, 20–23). This evidence concerns the gene MAP2K7 and Gorham-Stout disease.